While triple therapy combinations were prone to a higher incidence of AEs, these studies were the first to indicate that BRAFi/MEKi/anti-PD1/PDL1 combinations have the potential to increase the frequency of long-lasting antitumor responses in BRAF v600-mutant melanoma patients [58,60]. This evidence concerns the gene PDCD1 and melanoma.